RxDoctor Payments Data

Grant Corning, MD

Ophthalmology · Ada, OKNPI 1033259114

Payments from drug & device makers

$1,611in general payments, 2019–2025

Across 89 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Glaukos Corporation$177
  • The Cameron-ehlen Group, Inc.$134
  • Rxsight Inc$106
  • Sight Sciences, Inc.$58
  • AbbVie$49
  • plus $79 from 5 others

What the payments were for

  • Speaking & faculty fees$262%
  • Food & beverage$1,58598%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,611 in reported general payments places this provider in the 60th percentile of 183 ophthalmology providers in Oklahoma.

See all ophthalmology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$704,753
Medicare patients
1,115
Services billed
6,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine209$159,538
LumiganBimatoprost95$53,179
XiidraLifitegrast44$34,611
Prednisolone Acetate564$32,591
Ketorolac Tromethamine545$20,764
MoxifloxacinMoxifloxacin Hcl559$20,739
Fluorometholone185$18,949
Cyclosporine47$17,100
CombiganBrimonidine Tartrate/Timolol13$5,337
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$4,777
Latanoprost486$4,307
SimbrinzaBrinzolamide/Brimonidine Tart12$4,034
Tobramycin-DexamethasoneTobramycin/Dexamethasone32$2,577
ErythromycinErythromycin Base143$1,753
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat114$1,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$49$218,053317 claims
Bausch & Lomb Americas Inc.Xiidra$18$34,61144 claims
AlconSimbrinza$1,007$4,03412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 183 ophthalmology providers in Oklahoma.

Other ophthalmology in Ada

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →